GoodRx (GDRX) announced that the new higher dose Novo Nordisk’s (NVO) Wegovy HD injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx expands access to Eli Lilly’s new oral GLP-1 Foundayo
- GoodRx Reshapes Board After Director Resignation and Reclassification
- GoodRx Chief Accounting Officer Resigns for New Opportunity
- GoodRx announces resignation of Chief Accounting Officer Romin Nabiey
- Novo Nordisk (NVO) Wins FDA Nod for High-Dose Wegovy amid Surging Obesity Drug Demand